Statistics from Altmetric.com
We thank Ignatova and colleagues1 for their interest in our work regarding peginterferonα-ribavirin/protease inhibitor combination in hepatitis C virus-associated mixed cryoglobulinaemia vasculitis (HCV-MC),2 and in bringing new elements up for discussion.
Ignatova et al emphasise the priority to clear the virus in HCV-MC. They reported 65 patients with HCV-associated MC vasculitis who were treated with conventional immunosuppresive drugs only (n=30), monotherapy with interferon-alfa (n=9) or rituximab (n=8) or peginterferon-alfa/ribavirin±rituximab …
Competing interests None.
Provenance and peer review Commissioned; internally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.